Abstract:Abstract Background Moderate-to-severe ulcerative colitis (UC) can be associated with impairment in quality of life (Kawalec, 2016). Aims The Communicating Needs and Features of IBD Experiences (CONFIDE) study aims to increase understanding of patients’ experiences and the impact of IBD on their lives in the United States, Europe, Japan, and Canada. These data focus on Canadian patients. Methods An online, quantitative, cross-sectional survey was conducted (panel recruitment) between February and March 2023 in patients diagnosed with active moderate-to-severe UC in Canada. Moderate-to-severe UC was defined using criteria based on previous treatment, steroid use, and/or hospitalization. Data collected included patient perspectives on their experiences with UC, including symptom burden. Results were summarised descriptively. Results The survey was completed by 82 (of 373 contacted – 22% response) patients (65% male, mean age 43.5 years (SD 12.6), mean time since diagnosis 6.3 years (SD 7.6, range 1-33 years)). The top 3 patient-reported symptoms experienced in the past month were diarrhea (39%, n=32), bowel urgency (BU, 31%, n=25), and fatigue/tiredness (29%, n=24). Overall 73% (n=60/82) were receiving advanced therapies (biologic or novel oral therapy), and BU was currently experienced by 28% (n=17) of these patients. Over half of patients had ever experienced BU (56%, n=46); of these, 48% (n=22) reported doing so at least once a week in the past 3 months. Due to fear/anticipation of bowel urgency related accidents, 68% (n=56) of patients with UC reported wearing diaper/pad/protection at least once in the past 3 months. Of those who had worn diaper/pad/protection, 32% (n=18) reported that they suffered from BU in the past month. Due to fear of BU-related accidents, 31% (n=25) of patients declined participating in work/school, 34% (n=28) declined participating in social events, and 26% (n=21) declined participating in sports/physical exercise in the last 3 months. Conclusions Out of the top 3 symptoms reported by patients, BU was the second-most common in patients with moderate-to-severe UC in this study of Canadian patients. A substantial proportion of patients with moderate-to-severe UC continue to report BU, despite receiving advanced therapies; with two-thirds requiring to wear diapers or pads. Further work is needed to understand the pathophysiology of urgency and the efficacy of medical therapies to improve urgency using validated outcome measures. References Kawalec P. Indirect costs of inflammatory bowel diseases: Crohn's disease and ulcerative colitis. A systematic review. Arch Med Sci. 2016 Apr 1;12(2):295-302 Funding Agencies Eli Lilly and Company

S1352 Disease Characterization and Safety Contextualization in Patients with Ulcerative Colitis Using a Healthcare Administrative Database in the United States

Comparative of the effectiveness and safety of biological agents, small molecule drugs, and microbiome therapies in ulcerative colitis: Systematic review and network meta-analysis

Real-world effectiveness and safety of advanced therapies for the treatment of moderate-to-severe ulcerative colitis: Evidence from a systematic literature review

Real-World Effectiveness of Ustekinumab in Ulcerative Colitis in a United States Multicenter Cohort Consortium

Single-cell and microarray chip analysis revealed the underlying pathogenesis of ulcerative colitis and validated model genes in diagnosis and drug response

Clinically Significant Upper and/or Lower GI Events: a Novel, Composite Endpoint Used in Ongoing Studies to Evaluate the Gastrointestinal Safety in Arthritis Patients

Ulcerative colitis

Histologic assessments in ulcerative colitis: the evidence behind a new endpoint in clinical trials

Current Pharmacologic Options and Emerging Therapeutic Approaches for the Management of Ulcerative Colitis: A Narrative Review

P658 Safety and efficacy of MH002, an optimized live biotherapeutic product, for the treatment of mild to moderate ulcerative colitis: a first-in-disease, double-blind, randomized clinical trial

Ulcerative colitis: clinical biomarkers, therapeutic targets, and emerging treatments

Differential Mortality Outcomes Among Different Classes Of Drugs In Elderly Patients With Ulcerative Colitis Using A Multi-Center Research Network

Emerging drugs for the treatment of ulcerative colitis

Integrated Traditional Chinese and Western medicine for ulcerative colitis with diabetes

Safety assessment of sulfasalazine: a pharmacovigilance study based on FAERS database

A Comparison of the Efficacy and Safety of Complementary and Alternative Therapies for Ulcerative Colitis: A Protocol for Systematic Review and Meta-Analysis.

Ulcerative colitis: molecular insights and intervention therapy

A255 COMMUNICATING NEEDS AND FEATURES OF IBD EXPERIENCES (CONFIDE) SURVEY: PATIENT PERSPECTIVES ON EXPERIENCE OF ULCERATIVE COLITIS SYMPTOMS IN CANADA

Ulcerative colitis in a Southern European country: a national perspective

Global trends and hotspots of ulcerative colitis based on bibliometric and visual analysis from 1993 to 2022

Disease clearance in ulcerative colitis: A new therapeutic target for the future